A Study of STAR-0215 in Healthy Adult Participants
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human, single-center, randomized, double-blind, placebo-controlled, single
ascending dose study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics,
and immunogenicity of a single subcutaneous administration of STAR-0215 in healthy adult
participants.